Nabsys Electronic Genome Mapping Advances Cancer Analysis
Providence, Rhode Island, USA, September 17, 2026 Nabsys, Inc. has announced the publication of research from Augusta University demonstrating...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Providence, Rhode Island, USA, September 17, 2026 Nabsys, Inc. has announced the publication of research from Augusta University demonstrating...
PROVIDENCE, R.I., July 31, 2026 Nabsys 2.0, LLC has entered into a multi-year research collaboration with Indiana University School...
San Diego, California – May 17, 2026 Nabsys 2.0 announced the expansion of its OhmX™ electronic genome mapping (EGM)...
